In vitro, both the mTORC1/2i AZD2014 and the mTORC1i rapamycin, inhibited the growth of NR2F1-overexpressing cells, indicating that targeting mTORC1 may delay melanoma relapse. Here, NR2F1 is linked to melanoma.